DrugPatentWatch Database Preview

Brivaracetam - Generic Drug Details

« Back to Dashboard

What are the generic sources for brivaracetam and what is the scope of freedom to operate?

Brivaracetam is the generic ingredient in one branded drug marketed by Ucb Inc and is included in three NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brivaracetam has one hundred and forty-five patent family members in forty-one countries.

One supplier is listed for this compound.

Summary for brivaracetam

International Patents:	145
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	3
Suppliers / Packagers:	1
Bulk Api Vendors:	29
Clinical Trials:	34
Patent Applications:	580
DailyMed Link:	brivaracetam at DailyMed

Recent Clinical Trials for brivaracetam

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Utrecht University	Phase 2/Phase 3
Comprehensive Epilepsy Care Center for Children & Adults	Phase 2/Phase 3
Rosenfeld, William E., M.D.	Phase 2/Phase 3

See all brivaracetam clinical trials

Pharmacology for brivaracetam

Mechanism of Action

Epoxide Hydrolase Inhibitors

Synonyms for brivaracetam

(2S)-2-((4R)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide

(2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide

(2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butanamide

(2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide

1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-

2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide

2(s)-[2-oxo-4(r)-propylpyrrolidin-1-yl]butyramide

357336-20-0

AC-29289

ACN-055569

AKOS027324306

AN-16688

AS-35277

BDBM50422531

Brivaracetam (USAN/INN)

Brivaracetam [USAN:INN]

Briviact

Briviact (TN)

CHEBI:133013

CHEMBL607400

compound 83alpha

CS-3418

D08879

DB05541

EX-A2748

FT-0700965

GTPL9041

HY-14449

MSYKRHVOOPPJKU-BDAKNGLRSA-N

Rikelta

SB17229

SCHEMBL122081

U863JGG2IA

UCB 34714

UCB-34714

UCB34714

UNII-U863JGG2IA

ZINC3979899

US Patents and Regulatory Information for brivaracetam

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-001	May 12, 2016		RX	Yes	No
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-001	May 12, 2016		RX	Yes	No			Y	Y
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;INTRAVENOUS	205837-001	May 12, 2016		RX	Yes	Yes
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;ORAL	205838-001	May 12, 2016		RX	Yes	Yes			Y	Y
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;INTRAVENOUS	205837-001	May 12, 2016		RX	Yes	Yes			Y	Y
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;INTRAVENOUS	205837-001	May 12, 2016		RX	Yes	Yes			Y	Y
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;ORAL	205838-001	May 12, 2016		RX	Yes	Yes

International Patents for brivaracetam

Country	Patent Number	Estimated Expiration
Montenegro	P6109
Bulgaria	107004
Japan	2003523996
South Korea	100681580
Iceland	2754
Iceland	6481
Mexico	PA02008206

Supplementary Protection Certificates for brivaracetam

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1452524	C01452524/01	Switzerland		PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65830 06.10.2016
1452524	10/2016	Austria		PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 (MITTEILUNG) 20160118
1452524	530	Finland
1265862	PA2016013	Lithuania		PRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
1452524	16C1001	France		PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
1452524	122016000030	Germany		PRODUCT NAME: BRIVARACETAM ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1073 20160114
1452524	1690009-4	Sweden		PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073 20150114